Viimeisin päivitys :
19/11/2024
Epilepsialääkkeet   Fosphenytoin sodium  
Injektioneste
Stabilius liuoksessa Stabilius seoksissa Tekijät, jotka vaikuttavat stabiliuteen Yhteensopivuus Antotapa Viitteet pdf
   Kemiallinen rakenne  

Kauppanimi   Kauppanimi     

Trade names are indicative and excipients composition can be different depending on the country and manufacturers

Cerebryx Kanada, Yhdysvallat
Fosphen Intia
Fostoin Japani
Pro - Epanutin Hollanti, Irlanti, Islanti, Iso-Britannia, Itävalta, Luxemburg, Norja, Ruotsi, Suomi, Tanska
Prodilantin Belgia, Hollanti, Irlanti, Islanti, Iso-Britannia, Italia, Itävalta, Japani, Kreikka, Luxemburg, Puola, Ranska, Ruotsi, Saksa, Suomi, Sveitsi, Tanska, Unkari, Yhdysvallat
Viitteet   Injektioneste   Viitteet : Fosphenytoin sodium  
tyyppi julkaisu
800 Lehti Fischer JH, Cwik MJ, Luer MS, Sibley CB, Deyo KL.
Stability of fosphenytoin sodium with intravenous solutions in glass bottles, polyvinyl chloride bags, and polypropylene syringes.
Ann Pharmacotherapy 1997 ; 31: 553-559.
1412 Lehti Brett A, Riggs RM, Webster AA, Benner KW.
Y-site stability of fosphenytoin and sodium phenobarbital.
Int J Pharm Compound 1999 ; 3: 64-66.
1419 Lehti Riggs RM, English BA, Webster AA, McGuire JM, Riordan JM.
Fosphenytoin Y-site stability studies with lorazepam and midazolam hydrochloride.
Int J Pharm Compound 1999 ; 3: 235-238.
1803 Lehti Trissel, LA, Saenz CA, Ogundele OB, Ingram D, Baker MB.
Compatibility of fenoldopam mesylate with other drugs during simulated Y-site administration.
Am J Health-Syst Pharm 2003 ; 60: 80-85.
3379 Lehti Fox L.M, Wilder A.G, Foushee J.A.
Physical compatibility of various drugs with neonatal total parenteral nutrient solution during simulated Y-site administration.
Am J Health-Syst Pharm 2013 ;70:520-524.
3827 ilmoitus Ghazi I.M, Hamada Y, Nicolau D.P.
Compatibility of tedizolid phosphate with selected intravenous drugs via simulated Y-site conditions.
ASHP Midyear 2015
3829 ilmoitus So W, Kim L, Thabit A.K, Nicolau D.P, Kuti J.L.
Compatibility of isavunazonium sulfate during simulated Y-site administration.
ASHP Midyear 2015
3967 Lehti Staven V, Herra I, Wang S, Grönlie I,Tho I.
Physical compatibility of total parenteral nutrition and drugs in Y-site administration to children from neonates to adolescents.
J Pharm Pharmacol 2017 ;69,7:448-462
4145 Lehti Asempa T.E, Avery L.M, Kidd J.M, Kuti J.L, Nicolau D.P.
Physical compatibility of plazomicin with select i.v. drugs during simulated Y-site administration.
Am J Health-Syst Pharm 2018 ;75,14:1048-1056
4370 Lehti Staven V, Wang S, Gronlie I, Tho I.
Physical stability of an all-in one parenteral nutrition admixture for preterm infants upon mixing with micronutrients and drugs
EJHP 2018 2018;0:1-7
4428 Lehti Rashed S.M, Sweatman T.W, Thoma L, Hovinga C.A, Phelps S.J.
Chemical Compatibility of Depacon® with Medications Frequently Administered by Intravenous Y-Site Delivery in Patients with Epilepsy or Head Trauma.
J Pediatr Pharmacol Ther 2004 ; 9, 2: 126-132.
4433 Lehti Ghazi I.M, El Nekidy W.S, Sood A, Dulku A, Patel R, Patel K.
Y-site Administration of Imipenem/Cilastatin/ Relebactam With Common Intravenous Medications
Clin Ther 2020 ; 42, 3: 475-485.
4569 Lehti Lee T.M , Villareal C.L, Meyer L.M.
Y-Site Compatibility of Intravenous Levetiracetam With Commonly Used Critical Care Medications.
Hosp Pharm 2021 ; 56, 4: 282-286.
4801 Lehti Ruiz V, Yuwei Shen Y, Abouelhassan Y, Fouad A, Nicolau D, Kuti J.
Physical compatibility of sulbactam/durlobactam with select intravenous drugs during simulated Y-site administration.
Am J Health-Syst Pharm 2024 ;51,1:

  Mentions Légales